This paper is only available as a PDF. To read, Please Download here.
For almost two decades, two types of platelet products have been available: pooled random donor platelets (RDP), manufactured from whole blood donations and single donor platelets (SDP), manufactured on apheresis devices. During this period, two trends have occurred—an overall increase in demand for platelets and a preference for the use of SDP.
The reasons for the disproportionate increase in the use of SDP relates in all likelihood to supply logistics, perceptions of quality, lack of price sensitivity on the part of prescribing physicians, and minimizing donor exposures in an era of uncertainty and litigation surrounding the allogeneic blood supply.
In the cost-conscious 1990s, it is essential to reappraise the situation and perform a critical analysis of the relative value of these products. Such an analysis leads to an inescapable conclusion that preferential use of RDP is the more logical strategy.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Transfusion and Apheresis Science
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Platelet transfusion therapy.Transfus Med Rev. 1987; 3: 195-200
- Platelet transtusion therapy for the cancer patient.Semin Oncol. 1990; 17: 198-209
- Collection and transfusion of blood in the United States, 1982–1988.N Engl J Med. 1990; 322: 1646-1651
- Collection and transfusion of blood and blood components in the United States, 1992.Transfusion. 1995; 35: 802-812
- Data on apheresis, blood collection and transfusion related activities: statistical analyses of the American Association of Blood Banks institutional membership questionnaires.Transfusion. 1996; 36: 375-381
- Leukodepleted platelet apheresis production with a modified COBE Spectra collection protocol.J Clin Apher. 1995; 10: 85-86
- Research and development in the blood bank: efforts of a hospital donor center to improve efficiency in line leukocyte reduction filters for automated platelet pheresis.J Clin Apher. 1995; 10: 76-80
- Quality of platelet concentrates.Immun Invest. 1995; 24: 353-370
- In vitro assessment of the quality of stored platelet concentrates.Trans Med Rev. 1994; 8: 29-36
- Reports of 335 transfusion associated deaths: 1976–1985.Transfusion. 1990; 30: 583-590
- Septic reactions to platelet transfusions.J Am Med Assoc. 1991; 266: 555-558
- A prospective study of symptomatic bacteremia following platelet transfusion and its management.Transfusion. 1994; 34: 950-954
- The risk of transfusion transmitted viral infections.N Engl J Med. 1996; 334: 1685-1690
- A prospective randomized study of three types of plate concentrates in patients with hematological malignance corrected platelet count increments and frequency of non hemolytic febrile transfusion reactions.Trans Med. 1996; 6: 33-39
- A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions.Transfusion. 1993; 33: 794-797
- Prevalence of platelet transfusion reactions before and after implementation of leukocyte-depleted platelet concentrates by filtration.Vox Sanguinis. 1993; 65: 103-107
- In vitro and in vivo effects of pre-storage filtration of apheresis platelets.Transfusion. 1995; 35: 125-130
- Leukodepleted platelet concentrates prepared by in filtration of platelet rich plasma.Transfusion. 1995; 35: 131-136
- Donor selection of alloimmunized patients by platelet crossmatching of random donor platelet concentrates.Transfusion. 1990; 30: 314-317
- Comparison of demographics and motivations of highly committed whole blood and platelet donors.J Clin Apher. 1993; 8: 82-88
- A reappraisal of Hepatitis B virus vaccination strategies using cost-effective analysis.Ann Intern Med. 1993; 118: 298-306
- Effect of interferon treatment in patients with Hepatitis B antigen positive chronic Hepatitis B.Ann Intern Med. 1993; 119: 110-115
- Non A, non B post transfusion Hepatitis.Ann Intern Me. 1993; 119: 110-115
- Long term mortality after transfusion associated non A non B Hepatitis.N Engl J Med. 1992; 327: 1906-1911
- Cost effectiveness of single donor (SD) versus pooled platelet (PD) for avoiding donor exposures in primary coronary arteries bypass grafting (CABG).Transfusion. 1996; 36: 47S
- A comparison of filtered leukocytereduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion associated CM infection after bone marrow transplant.Blood. 1995; 86: 3598-3603
- Analysis of leukocyte subsets in leukoreduced products.in: Proc 20th Annual Meeting, MAABB, Towson, MDApril, 1997
© 1997 Published by Elsevier Inc.